Glen Harbor Capital Management’s Corcept Therapeutics CORT Stock Holding History

Glen Harbor Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-9,632	Closed	-$107K	–	1334
2019 Q2	$107K	Buy	9,632 +624	+7%	+$6.95K	﹤0.01%	1156
2019 Q1	$106K	Hold	9,008	–	–	﹤0.01%	1142
2018 Q4	$120K	Buy	9,008 +720	+9%	+$9.52K	﹤0.01%	1085
2018 Q3	$116K	Buy	8,288 +2,272	+38%	+$31.8K	﹤0.01%	1173
2018 Q2	$95K	Hold	6,016	–	–	﹤0.01%	1146
2018 Q1	$99K	Buy	+6,016	New	+$111K	﹤0.01%	1152

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Glen Harbor Capital Management's CORT Position: Q3 2019 in Review

Glen Harbor Capital Management sold out of Corcept Therapeutics (CORT) in Q3 2019, closing a stake of 9,632 shares — an estimated $107K sold.

Glen Harbor Capital Management first reported a position in CORT in Q1 2018 and held it in 6 quarters. The position peaked at $120K in Q4 2018. 193 funds tracked by Wall St. Rank hold CORT as of Q3 2019.

Glen Harbor Capital Management reported no remaining Corcept Therapeutics position as of Q3 2019 after selling out during the quarter.
Glen Harbor Capital Management sold 9,632 Corcept Therapeutics shares in Q3 2019, an estimated $107K.
Glen Harbor Capital Management first reported a position in Corcept Therapeutics in Q1 2018 and held it in 6 quarters.
Glen Harbor Capital Management's Corcept Therapeutics position peaked at $120K in Q4 2018.
193 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.